I completely agree - every concerned shareholder should

New Post Public Reply Private Reply Replies (1) Message Board
thesmalls
I completely agree - every concerned shareholder should write Bill and convey their thoughts directly with respect to this unprofessional behavior below. If Bill condones it - then it will make my decision easier to move on.

I normally wouldnt even address a post such as this but when it comes as, once again, another defensive attack from what isis supoosed to be an ambassador for the brand/shareholders - one should respond and let other shareholders decide for themselves what type of mouthpiece is best for the company.

- I am not a "basher." Far from it. I am a stockholder with well into 8 figures and a cost basis that was steadilysteadily increasing until recently. You dont want me to sell. PPS cant absorb the constant selling from VNDM now and which IR seems to have no answers for.

- My concern is (was?) directly with the handling of information or lack thereof with IR/muse. That seems to be rather obvious with most of the readers on here. The concerns seem genuinely mutual with the heart of my issues. If you take that as "bashing" then you/your organization need to really brush up on your understanding of the OTC dynamics, manipulation, and what real "bashers" do and how they manipulate. Based on the preponderence of evidence and circumstance combined with the stock price before/after IR took over and the emergence of dilutive MMs - it looks more like a "pump n dump" on your part than bashing on mine. DD and asking for direct answers in a public disclosure format IS NOT bashing. It is due diligence which is even more critical in this realm. You are a penny stock that is now back in trips - NOT a blue chip. Understand the difference.

- You /the company STILL refuse to address the critical questions that have been asked and "skirted" around and caused myself and others to show public concern:

1. What is the name of your firm? (Why in the world would this be confidential - goes sfraight to credibility and transparency for investors)

2. How are you compensated? This goes straight to bias/vested interest. Very straightforward and you have given conflicting answers. This should NOT be a secret. Goes straight to credibility based on bias. Granted - paid agents of former toxic lenders were disruptive of CCs, Timken, etc.

3. Guidance on revenue. Again - very different from what you are responding to. Bill provided very specific goals/targets in biz plan that has since been abolished and being reconstructed in 90 day plan. What is 2016 year end guidance range and/or when will IR/company provide it. Announcing SLAs 12-24 months out that may or may not come to fruition is NOT the same as saying: "We expect revenues to be between $500K and $2.5MM in 2016. Tighter guidance is not prudent at this time due to the nature of being a start up and the switching of revenue generation from in house to 3rd party licensing/SLA agreements." Straightforward. Real numbers. Not esoteric numbers with no definitive terms or contracts with teeth. Why is this difficult? Why keep ignoring the real question? I have been specific. Bill gave a 5 year revenue projection in biz plan along with decreasing OS that many long term investors considered the "fundamentals ". What are those new fundamentals and/or when will they specifically be updated? If these agreements and deals are specific in terms of start dates and production values - baselines should be straightforward on the minimum side of guidance.

I will address others later due to time constraints now.

You are quickly losing credibility trying to dismiss my valid concerns by lumping me in with them is rather silly when looking at my entire posting history here and elsewhere let alone completely unprofessional and flat out wrong. Worse, when you have an actual, long term investor that has been rather complimentary to the company at large over the last 12-24 months ask critical questions and then lambast me as a basher - you actually provide easy fodder for the real detractors on iLie to have a field day with your comments. If you arent going to address the specific questions and concerns above - do us all a favor and say nothing. I and other long term shareholders that i personally correspond with cant help but notice the direct correlation between the stock price and your emergence. Worse, the price spike prior to VNDM showing up and continually unloading shares driving the price down (again - fodder for the P&D argument).

For other concerned shareholders, I suggest you write to CEO directly if you find this type of response unproductive, unprofessional, and counter intuitive to the role that seems to be regular IR groups. Alienating long term investors with critical questions is NOT conducive to fostering respect, loyalty, and creating long term holders. Having me sell and move on tanks the price and forces others to sell. That imbalance from a large shareholder leaving becomes easy fodder for MM to naked short with little risk. How exactly does that strengthen the company and/or help shareholders...?

Again - if you are concerned as I am - go to Bill directly.



"Greetings TPAC Shareholders.

There are “shareholder concern” posts on places like IHUB and now Investors Hang Out. (In particular addressing the alias – thesmalls-- on Investors Hangout)

The post states that TPAC/IR skirts around revenue inquiries (among a list of other things that won’t be addressed here). This is so far from the truth. The IH subscriber that posted such information has made inaccurate and false accusations. The post stated that there is a disconnect. I would like for this to truly be a disconnect but I am now sure it isn’t.

It has been approved by CEO Bill McKay, as of May 4th, that IR can release deal structure information for the following forms of business dealings during the reconstruction:

• All contracts, of type purchase orders, Licensing Agreements, Service Level Agreements, PF Share agreements/distributions and OS structure information.

IR has tweeted that we could not extract information prior to the reconstruction period however since then we have provided direct information when requested for:
• O/S directly from the TA
• Deal structure including revenue time frame Licensing Agreement
• Deal Structure including revenue time frame Service Level Agreement

The revenue standard has been lowered from $250K to $75K (which should be restored)

IR has even provided news on Request for Quotes.

This is a new standard for TPAC"

Trans-Pacific Aerospace (TPAC) Stock Research Links

TPAC Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 5

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

TCTM KIDS IT Education Inc. Announces 2024 Annual Report

Updated Category News Views 322

TCTM KIDS IT Education Inc. Issues 2024 Annual Report TCTM KIDS IT EDUCATION INC. (NASDAQ: VSA), a prominent leader in IT-focused supplementary STEM education, has officially filed its annual report on Form 20-F for the fiscal year ending December 31, 2024, with the Securities and Exchange Commission (SEC). This filing reflects the company’s ongoing commitment to...

Continue Reading
Polaris Celebrates Commitment to Community and Environment

Updated Category News Views 224

Polaris Revolutionizes Commitment Through Geared For Good Report Polaris continues to ensure sustainability and responsible stewardship across its operations, supporting its employees, riders, communities, and the environment. The recently released report illustrates Polaris Inc.'s (NYSE: PII) dedication to these values. Impacting Lives Through Corporate Responsibility...

Continue Reading
AgentCoach.AI Transforms Real Estate Coaching with AI Tools

Updated Category News Views 195

AgentCoach.AI Revolutionizes the Coaching Landscape Real Estate Professionals Gain Access to On-Demand Expertise and Tools for a Fraction of Traditional Coaching Costs AgentCoach.AI is excited to introduce its innovative AI-powered coaching platform tailored specifically for real estate agents. This groundbreaking service is designed to streamline everyday tasks, enhance...

Continue Reading
Unleash Creativity: LEGO's 2025 Workshop Series for Kids

Updated Category News Views 460

LEGO Group Launches Exciting 2025 Creativity Workshop Series The LEGO Group is thrilled to introduce its innovative 2025 Creativity Workshop Series, offering young creators a fantastic opportunity to unleash their imagination. Tailored for children aged 6 to 12, these engaging workshops will take place at select LEGO stores, providing both in-person and online...

Continue Reading
Kering Overview: Enhanced Share Liquidity Insights for Growth

Updated Category News Views 132

Kering Overview: Enhanced Share Liquidity Insights for Growth Kering has recently shared a detailed report on its share liquidity mandate which outlines the company's achievements during the first half of the year. This report sheds light on the performance and trading activity of Kering shares as per its engagement with Rothschild Martin Maurel. There is an evident...

Continue Reading